The drug, Aduhelm, a monthly infusion priced at $56,000 per year, was approved this week despite weak evidence that it helps patients.The drug, Aduhelm, a monthly infusion priced at $56,000 per year, was approved this week despite weak evidence that it helps patients.your-feed-science, Alzheimer’s Disease, Drugs (Pharmaceuticals), Clinical Trials, Aduhelm (Drug), Elderly, Biogen IncRead More
